Literature DB >> 23070724

Postradiation sarcoma after radiotherapy for nasopharyngeal carcinoma.

Jimmy Yu Wai Chan1, Stanley Thian Sze Wong, Gregory Ian Siu Kee Lau, William Ignace Wei.   

Abstract

OBJECTIVES/HYPOTHESIS: Postradiation sarcoma (PRS) is a notorious complication after radiotherapy (RT). The prognosis is poor, and the role of surgery is not well defined. The aim of our study was to review our experience in the management of PRS after RT for nasopharyngeal carcinoma (NPC). STUDY
DESIGN: Case series.
METHODS: Between 1998 and 2011, all patients treated for PRS after radiation for NPC were reviewed retrospectively.
RESULTS: Twenty-five patients were included. The mean latency period for the development of PRS after previous RT was 12.4 years. The histologic subtypes included osteosarcoma (n = 8), rhabdomyosarcoma (n = 6), undifferentiated sarcoma (n = 6), malignant fibrous histiocytoma (n = 4), and leiomyosarcoma (n = 1). Twenty patients underwent surgery with curative intent, but 14 of them eventually had microscopic positive resection margins. Among them, all received postoperative adjuvant chemoradiation, and six of them had brachytherapy as well. However, 71.4% of them eventually developed local recurrence. The median survival was significantly better for those with clear margin resection than for those with positive margins (5.12 years vs. 1.44 years, P = .04). Surgery was effective in symptom palliation, including tumor pain, bleeding, and trismus.
CONCLUSIONS: PRS remains a disease with poor prognosis. Surgical resection with clear margins achieves significantly better survival. Surgery is also effective in the palliation of pain, bleeding, and trismus in patients with advanced staged disease.
Copyright © 2012 The American Laryngological, Rhinological, and Otological Society, Inc.

Entities:  

Mesh:

Year:  2012        PMID: 23070724     DOI: 10.1002/lary.23282

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  Mdm2 and p53 Expression in Radiation-Induced Sarcomas of the Head and Neck: Comparison with De Novo Sarcomas.

Authors:  Min Jeong Song; Joon Seon Song; Jong-Lyel Roh; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim; Sung Bae Kim; Sang-Wook Lee; Kyung-Ja Cho
Journal:  Korean J Pathol       Date:  2014-10-27

2.  Radiation-induced sarcomas of the head and neck in post-radiation nasopharyngeal carcinoma.

Authors:  Qiuxia Yang; Yunxian Mo; Qianqian Zhao; Xiaohua Ban; Mingyan He; Peiqiang Cai; Xuewen Liu; Chuanmiao Xie; Rong Zhang
Journal:  Radiol Med       Date:  2016-10-13       Impact factor: 3.469

Review 3.  Radiation-Induced Sarcomas of the Head and Neck: A Systematic Review.

Authors:  Andrés Coca-Pelaz; Antti A Mäkitie; Primož Strojan; June Corry; Avraham Eisbruch; Jonathan J Beitler; Sandra Nuyts; Robert Smee; Johannes A Langendijk; William M Mendenhall; Cesare Piazza; Alessandra Rinaldo; Alfio Ferlito
Journal:  Adv Ther       Date:  2020-11-13       Impact factor: 3.845

4.  Radiation-Induced Sarcoma of the Head and Neck Following Radiotherapy for Nasopharyngeal Carcinoma: A Single Institutional Experience and Literature Review.

Authors:  Jianlin Lou; Lin Jiang; Xinshen Dai; Huanhuan Wang; Jia Yang; Liang Guo; Meiyu Fang; Shengye Wang
Journal:  Front Oncol       Date:  2021-01-21       Impact factor: 6.244

5.  Clinical Characteristics and Predictive Outcomes of Recurrent Nasopharyngeal Carcinoma-A Lingering Pitfall of the Long Latency.

Authors:  Yung-Hsuan Chen; Sheng-Dean Luo; Shao-Chun Wu; Ching-Nung Wu; Tai-Jan Chiu; Yu-Ming Wang; Yao-Hsu Yang; Wei-Chih Chen
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.